Advanced Solid Tumor Clinical Trial
Official title:
A Phase I, First-In-Human, Multicenter, Open-Label Dose Escalation and Dose Expansion Study of ABM-1310, as a Monotherapy and a Combination Therapy, Administered Orally in Adult Patients With Advanced Solid Tumors Harboring BRAF Mutations
Verified date | May 2024 |
Source | ABM Therapeutics Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase I, First-In-Human, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with locally advanced or metastatic solid tumors who have no effective standard treatment options available, as monotherapy in patients with documented BRAF V600 mutation, or in combination with cobimetinib (Cotellic®) in adult patients who have documented BRAF mutation and progressive disease or intolerance to at least one prior line of systemic therapy.
Status | Terminated |
Enrollment | 53 |
Est. completion date | April 5, 2024 |
Est. primary completion date | April 5, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male and female subjects age 18 years and older who are able to sign informed consent and to comply with the protocol 2. Patients with histologically or cytologically-documented, locally advanced, or metastatic solid tumor malignancy that has either (a) progressed on at least one line of prior standard systemic therapy, (b) for which no standard therapy exists, or (c) standard therapy is not considered appropriate by the patient or treating physician. There is no limit to the number of prior treatment regimens - Part A: Patients with advanced or metastatic solid tumors with documentation of positive BRAF V600E mutation, or any other BRAF V600 mutation is required for enrollment - Part B: Patients with advanced or metastatic solid tumors with documentation of any BRAF mutation. - Part C: 1. C-1: Patients with primary central nervous system (CNS) tumors and documentation of positive BRAF V600 mutation 2. C-2: Patients with advanced or metastatic solid tumors and documentation of positive BRAF V600 mutation excluding primary CNS tumor 3. C-3: Patients with advanced or metastatic solid tumors and documentation of positive BRAF mutation including primary CNS tumors but excluding melanoma with brain metastasis 4. C-4: Patients with melanoma with brain metastasis and documentation of positive BRAF mutation Patients with active or stable brain metastasis that are asymptomatic, or that are symptomatic treated with a total daily dose of no more than 4 mg of dexamethasone (or equivalent) that is stable or tapering for at least 2 weeks prior to first treatment are eligible for enrollment. Patients with neurologic signs and symptoms who are not being treated with steroids are eligible and should have no experience of seizure within 2 weeks prior to first treatment. 3. Must have at least one measurable lesion as defined by RECIST V1.1 criteria for solid tumors or the RANO criteria for primary CNS tumors, such as gliomas. - For solid tumor with Brain Metastases: - Measurable brain lesions that are 0.5 - 3 cm in longest diameter as defined by the modified RECIST V1.1 criteria are allowed. - Brain lesion size > 3 cm is not eligible. 4. ECOG performance status of 0 or 1 or Karnofsky performance status of = 70 5. Adequate organ function confirmed at screening and within 28 days of initiating treatment, as evidenced by: - Absolute Neutrophil Count (ANC) = 1.0 x 10^9/L - Hemoglobin (Hgb) = 9 g/dl - Platelets (Plt) = 100 x 10^9/L - AST/ALT = 2.5 x Upper Limit of Normal (ULN) or = 5.0 x ULN if liver metastases are present - Total bilirubin = 1.5 x ULN, or direct bilirubin <ULN for patients with total bilirubin levels >1.5 ULN - Serum creatinine <1.5 x ULN or measured or calculated (per institutional standard) creatinine clearance of > 60 mL/min. 6. Negative pregnancy test within 72 hours before starting study treatment in all pre-menopausal women and women <12 months after the onset of menopause 7. Male and female subjects must agree to take sufficient contraceptive methods to avoid pregnancy before first dose of study treatment, during the study, and for at least 3 months after ceasing study treatment Exclusion Criteria: 1. Women who are pregnant or breast-feeding 2. Women of child-bearing potential (WOCBP) who does not use adequate birth control 3. Patients with any hematologic malignancy. This includes leukemia, lymphoma, and multiple myeloma 4. Have a second primary malignancy that, in the judgment of the investigator, may affect the interpretation of results 5. Patients with carcinomatous meningitis (leptomeningeal disease (LMD)) 6. Patients with history of stroke = 6 months prior to starting study drug 7. Patients who have had an experience of seizure within 14 days prior to first treatment 8. Impaired cardiac function or clinically significant cardiac diseases, including but not limited to any of the following: - Left Ventricular Ejection Fraction (LVEF) < 45% as determined by MUGA scan or ECHO - Congenital long QT syndrome - QTcF = 450 msec (mean) on screening (Triplicate 12-Lead ECG) - Unstable angina pectoris = 6 months prior to starting study drug - Acute myocardial infarction = 6 months prior to starting study drug - Use of pacemaker 9. Patients with - Unresolved diarrhea = CTCAE Grade 2, or - Impairment of gastrointestinal (GI) function, or - GI disease or conditions that may significantly alter the absorption of ABM-1310 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) 10. Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., uncontrolled hypertriglyceridemia [triglycerides >500 mg/dL], active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol 11. Extensive prior radiotherapy to more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation within 5 years 12. Patients who have received chemotherapy, targeted therapy or immunotherapy = 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy, except: - = 6 weeks for nitrosourea or mitomycin-C - = 5 half-lives or 2 weeks for small molecule inhibitor treatment, whichever is longer 13. Patients who have received wide field radiotherapy = 4 weeks, limited field radiation for palliation = 2 weeks, prior whole-brain radiotherapy (WBRT) = 4 weeks or stereotactic radiosurgery (SRS) = 2 weeks (one week for patients with primary CNS tumor such as GBM or with brain metastasis) prior to starting study drug or patients who have not recovered from side effects of such therapy 14. Patients who have undergone major surgery = 4 weeks in general prior to starting study drug or who have not recovered from side effects of such therapy. However, a minimum of 2 weeks recovery time from major surgery prior to starting study drug is acceptable if in investigator's opinion the patient has recovered from surgery. 15. Patients who are currently receiving treatment with therapeutic doses of warfarin sodium or any other coumarin-derivative anticoagulants 16. Patients who have received systemic corticosteroids = 2 weeks prior to starting study drug or who have not recovered from the side effects of such treatment. Therapeutic doses of corticosteroids up to 4 mg/day of dexamethasone, or equivalent are allowed. Note: Patients that are taking replacement doses of steroids are eligible 17. Patients who are currently receiving treatment with medication that has known risk to prolong the QT interval, and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug 18. Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory; patients with well controlled HIV might be enrolled per investigator's discretion) 19. Known history of active infection with Hepatitis B (e.g., HBsAg reactive), or Hepatitis C (e.g., S RNA (qualitative) is detected) 20. History of alcohol or drug abuse = 3 months prior to first dose 21. Has a history or current evidence of any condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might confound the results of the trial, interfere with the patient's participation and compliance in the trial |
Country | Name | City | State |
---|---|---|---|
United States | Robert H. Lurie Comprehensive Cancer Center (Northwestern University) | Chicago | Illinois |
United States | Henry Ford Cancer Institute | Detroit | Michigan |
United States | MD Anderson Cancer Center | Houston | Texas |
United States | UTHealth Science Center Houston Department of Neurosurgery | Houston | Texas |
United States | University of Miami Hospital Sylvester Comprehensive Cancer Center | Miami | Florida |
United States | Columbia University Medical Center | New York | New York |
United States | University of California- San Francisco | San Francisco | California |
United States | Stanford University School of Medicine | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
ABM Therapeutics Corporation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Exploratory preliminary efficacy in patients by types of BRAF V600 mutation | Preliminary efficacy of ABM-1310 as a single agent and in combination therapy | Up to study discontinuation (an average of 1 year) | |
Other | Identification of major metabolite of ABM-1310 in patients who receive ABM-1310 monotherapy in Part C | Tests to identify major metabolite of ABM-1310 by a central lab on the post-dose blood samples from patients who receive ABM-1310 monotherapy in Part C | Up to study discontinuation (an average of 1 year) | |
Primary | Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) | Determine Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) as a monotherapy and in combination therapy in Part A and Part B | End of Cycle 1 (each cycle is 28 days) or up to treatment discontinuation (an average of 6 months) | |
Primary | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | Safety and tolerability of ABM-1310 as a monotherapy and in combination therapy at Part A and Part B's Recommended Phase 2 dose (RP2D) in Part C | Up to study discontinuation (an average of 1 year) | |
Primary | Number of participants with abnormal laboratory values | Safety and tolerability of ABM-1310 as a monotherapy and in combination therapy at Part A and Part B's Recommended Phase 2 Dose (RP2D) in Part C | Up to study discontinuation (an average of 1 year) | |
Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | Safety and tolerability of ABM-1310 as a single agent and in combination therapy in Part A and Part B | Up to 30 days from treatment discontinuation | |
Secondary | Number of participants with abnormal laboratory values | Safety and tolerability of ABM-1310 as a single agent and in combination therapy in Part A and Part B | Up to 30 days from treatment discontinuation | |
Secondary | Area under the concentration time curve (AUC) | Pharmacokinetic (PK) profile of ABM-1310 as a single agent and in combination therapy | Up to Day 1 of Cycle 2 (each cycle is 28 days) | |
Secondary | Maximum plasma concentration (Cmax) | Pharmacokinetic (PK) profile of ABM-1310 as a single agent and in combination therapy | Up to Day 1 of Cycle 2 (each cycle is 28 days) | |
Secondary | Steady-state concentration (Css) | Pharmacokinetic (PK) profile of ABM-1310 as a single agent and in combination therapy | Up to Day 1 of Cycle 2 (each cycle is 28 days) | |
Secondary | Time to maximum plasma concentration (Tmax) | Pharmacokinetic (PK) profile of ABM-1310 as a single agent and in combination therapy | Up to Day 1 of Cycle 2 (each cycle is 28 days) | |
Secondary | Half-life (T1/2) | Pharmacokinetic (PK) profile of ABM-1310 as a single agent and in combination therapy | Up to Day 1 of Cycle 2 (each cycle is 28 days) | |
Secondary | Objective Response Rate (ORR) | Preliminary efficacy of ABM-1310 as a single agent and in combination therapy | Up to study discontinuation (an average of 1 year) | |
Secondary | Disease Control Rate (DCR) | Preliminary efficacy of ABM-1310 as a single agent and in combination therapy | Up to study discontinuation (an average of 1 year) | |
Secondary | Duration of Response (DOR) | Preliminary efficacy of ABM-1310 as a single agent and in combination therapy | Up to study discontinuation (an average of 1 year) | |
Secondary | Progression free survival (PFS) | Preliminary efficacy of ABM-1310 as a single agent and in combination therapy | Up to study discontinuation (an average of 1 year) | |
Secondary | Overall Survival (OS) | Preliminary efficacy of ABM-1310 as a single agent and in combination therapy | Up to study discontinuation (an average of 1 year) | |
Secondary | Time to Response (TTR) | Preliminary efficacy of ABM-1310 as a single agent and in combination therapy | Up to study discontinuation (an average of 1 year) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05515185 -
B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors
|
Early Phase 1 | |
Completed |
NCT05508100 -
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT02836600 -
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04890613 -
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
|
Phase 1 | |
Recruiting |
NCT04390737 -
Evaluate the Safety and Clinical Activity of HH2853
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007482 -
A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04108676 -
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
|
Phase 1 | |
Recruiting |
NCT05798611 -
Study of ART0380 in Patients With Biologically Selected Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05076396 -
PM14 Administered Intravenously to Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06008366 -
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06054932 -
Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04825392 -
A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06365918 -
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
|
Phase 1 | |
Recruiting |
NCT05443126 -
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05569057 -
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT05461287 -
Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors
|
Phase 1 |